美股异动丨福泰制药盘前大跌超14% Q2扭亏为盈但VX-993试验失败

Core Viewpoint - Vertex Pharmaceuticals (VRTX.US) experienced a significant pre-market decline of over 14% following the announcement of its second-quarter financial results and the failure of a key clinical trial [1] Financial Performance - The company's non-GAAP net profit for the second quarter was $4.52 per diluted share, compared to a loss of $12.83 per share in the same period last year [1] - Revenue for the three months ended June 30 increased from $2.65 billion to $2.96 billion year-over-year, surpassing analyst expectations of $2.91 billion [1] Clinical Trial Update - Vertex announced that the Phase II study of VX-993 for the treatment of postoperative pain following bunion surgery did not meet its primary endpoint [1] - As a result of these findings, the company stated it will not pursue VX-993 further as a monotherapy for acute pain [1]